 Zacks Investment Research upgraded shares of Adverum Biotechnologies NASDAQ:ADVM from a sell rating to a hold rating in a research report report published on Tuesday, Zacks.com reports. According to Zacks, Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide ... 